21 May 2009
Immunosuppression for composite tissue transplantations
B D KahanAnn Transplant 2009; 14(1): 20-20 :: ID: 880271
Abstract
Composite tissue transplantation refers to the grafting of skin, subcutaneous
tissue, muscle tendons, nerves, vascular tissues and bone generally to replace
injuries. On the one hand, these grafts do not provide or extend life as is the case for organ transplants. Thus, the threshold for adverse sequelae of immunosuppressive therapy is far lower than that for vital transplantations. In particular susceptibility to end organ toxicity, opportunistic infections and
increased risk of neoplasms represents appreciable risk to quality of life and
possibly survival. On the other hand, the composite mass represents a large
antigenic load with skin being the most immunogenic tissue. However, bone
marrow is a source of hematolymphopoietic stem cells which in experimental animals serve as vectors of alloacceptance or of chimerism. As low as 1% donor chimerism of the hybrid immune system might produce bidirectional donor: host tolerance. In the report by Granger, peripheral microchimerism
occurred only transiently in hand transplantation. Furthermore, the risk of graft versus host disease must be balanced against the emergence of CD8+/ TCR facilitating cells as described by Ilstad to induce tolerogenic regulatory T cells which have the CD4+/CD25+ high/Fox P3/CCR4/CLA/CCR6 phenotype as described by Hirahara. The latter state is more likely to emerge following nonmyeloablative recipient conditioning with 2000cGyTBI combined with fludarabine and immunosuppression. Whereas triple immunosuppression has been widely employed for this purpose, induction with alemtuzumab has been followed by dual maintenance therapy with tacrolimus plus mycophenolate mofetil or tacrolimus plus prednisone in recent cases. The roles of agents blocking adhesion molecules or of adjunctive cutaneous drug application remain under active investigation.
In Press
08 Mar 2024 : Original article
Association of Coronary Calcium Score on Cardiac PET During Pre-Kidney Transplant Assessment with Persisten...Ann Transplant In Press; DOI: 10.12659/AOT.943532
14 Mar 2024 : Original article
Impact of Blood Products Transfusion on Patients in the Immediate Post-Lung Transplant Period: A Cohort StudyAnn Transplant In Press; DOI: 10.12659/AOT.943652
14 Mar 2024 : Case report
Treatment of Cavernous Transformation of Portal Vein Caused by Hepatic Cystic Echinococcosis Using Ex Vivo ...Ann Transplant In Press; DOI: 10.12659/AOT.942358
15 Mar 2024 : Review article
Approaches and Challenges in the Current Management of Cytomegalovirus in Transplant Recipients: Highlighti...Ann Transplant In Press; DOI: 10.12659/AOT.941185
Most Viewed Current Articles
05 Apr 2022 : Original article
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
12 Jan 2022 : Original article
Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...DOI :10.12659/AOT.934738
Ann Transplant 2022; 27:e934738
22 Nov 2022 : Original article
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
15 Mar 2022 : Case report
Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...DOI :10.12659/AOT.935860
Ann Transplant 2022; 27:e935860